The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it continues to struggle with recent challenges, an analyst said.

CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it ...

CVS Caremark to pay $95M in Medicare fraud case A federal judge ruled in favor of a whistleblower, finding CVS’ pharmacy benefit manager Caremark overbilled Medicare for generic drugs.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Health’s pharmacy benefit manager, Caremark, has been ordered to pay $95 million for overbilling Medicare Part D drug reimbursements, a federal judge ruled Wednesday — a decision that ...

CVS Caremark has been ordered to pay $95 million after a federal judge found the pharmacy benefit manager improperly inflated Medicare Part D drug prices by failing to report required pharmacy ...

CVS Health’s Caremark business signed a new pharmacy benefits contract with the California Public Employees’ Retirement System, known as Calpers.